Sulfacarbamide

CHEMBL139877 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
215.2 g/mol
LogP
-1.5
Phase
4

Sulfacarbamide (urea sulfate) is a sulfonamide compound combining sulfanilamide activity with urea properties, used historically as a topical antiseptic and in urinary tract infection treatment. As a sulfonamide, it competitively inhibits dihydropteroate synthase in susceptible bacteria, blocking folate synthesis. It has been largely replaced by more effective and better-characterized antimicrobial agents.

分子量

215.2300 g/mol

LogP

-1.50

TPSA

124.00 Ų

リピンスキーの五則

適合

作用機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NC(=O)NS(=O)(=O)c1ccc(N)cc1

InChI

InChI=1S/C7H9N3O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,8H2,(H3,9,10,11)

Molecular Formula

C7H9N3O3S

HBD / HBA

3 / 4

回転可能結合数

2

重原子数

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Sulfacarbamide (urea sulfate) is a sulfonamide compound combining sulfanilamide activity with urea properties, used historically as a topical antiseptic and in urinary tract infection treatment. As a sulfonamide, it competitively inhibits dihydropteroate synthase in susceptible bacteria, blocking folate synthesis. It has been largely replaced by more effective and better-characterized antimicrobial agents.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Sulfacarbamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL139877. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11033. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.